OEA Supplementation Boosts Gut Health and May Offer Metabolic Benefits
Emerging research suggests that oleoylethanolamide (OEA) supplementation may positively influence gut health by increasing levels of beneficial bacteria and improving gut barrier function. A recent study published in Gut Microbes Reports indicates that daily supplementation with 300mg of Saanroo’s Trpti-branded OEA can lead to improvements in gut microbiome composition and immune function in adults with obesity.
The Gut-OEA Connection: A Closer Look
The randomized, double-blind, placebo-controlled trial involved 44 obese adults and revealed that OEA supplementation selectively enriched beneficial gut bacteria, particularly Akkermansia muciniphila and Faecalibacterium prausnitzii. These bacteria are recognized for their anti-inflammatory properties and their role in maintaining the integrity of the intestinal mucus layer. [1]
What is Akkermansia muciniphila?
Akkermansia muciniphila is a Gram-negative, anaerobic bacterium that colonizes the gut during the first year of life. It accounts for approximately 3% of the human gut microbiota and plays a crucial role in maintaining a healthy intestinal barrier. Its abundance is inversely correlated with BMI, type 1 diabetes, and bowel disease. [1] A. Muciniphila produces nutrients that feed intestinal cells, supporting the production of the mucus layer that controls gut permeability and low-grade inflammation. [4]
Study Findings: Improvements Beyond Microbiome Composition
Beyond changes in gut bacteria, the study similarly demonstrated improvements in gut barrier function. Researchers observed increases in occludin, a protein vital for tight junctions and barrier integrity, and shifts in immune markers, including increased interleukin-2 and decreased interleukin-1β. [1] Functional metagenomics indicated enhanced antioxidant, redox, and amino acid metabolism pathways, suggesting targeted improvements in gut homeostasis.
How Does OEA Work?
Oleoylethanolamide (OEA) is a fatty acid amide naturally produced by the body. It signals to the brain that the body is full, binding to GPR-119 to produce GLP-1 in the intestines. [2] Trpti, Saanroo’s bioavailable form of OEA, utilizes LipiSperse® technology by Pharmako Biotechnologies Pty Ltd to enhance intestinal delivery and maximize the production of the body’s own GLP-1. [3] This process supports metabolic function, satiety, and weight management. [2]
Trpti: A Bioavailable OEA Solution
Saanroo launched its Trpti-branded OEA at Expo West in 2025. [1] The LipiSperse® technology ensures efficient delivery of OEA to the intestines, potentially offering benefits without the side effects associated with synthetic GLP-1 agonists. [2] Clinical research suggests that 300mg of Trpti taken with food can significantly increase GLP-1 levels naturally within the body and reduce levels of DPP-4, an enzyme that degrades GLP-1. [2]
Future Research
The researchers involved in the Gut Microbes Reports study emphasize the necessitate for further investigation to fully elucidate the mechanisms of action of OEA and to explore potential dose-response relationships and individual variability. [1]